MedTrace Logo

To Demonstrate the Relative Bioavailability of Bupropion HCI 100 mg Tablets Under Fasting Conditions

NCT00883155 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2017-03-29

No results posted yet for this study

Summary

To Demonstrate the Relative Bioavailability of Bupropion HCI 100 mg Tablets under Fasting Conditions.

Conditions

  • Healthy

Interventions

DRUG

Bupropion HCl 100 mg Tablets (Invamed Inc.)

DRUG

Wellbutrin 100 mg Tablets (Glaxo Wellcome)

Sponsors & Collaborators

Principal Investigators

  • Jameel Razack, M.D. · Pharma Medica Research, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
1998-10-31
Primary Completion
1998-10-31
Completion
1998-10-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00883155 on ClinicalTrials.gov